

IOL Chemicals and Pharmaceuticals Limited Q1FY24 Investor Presentation August 2023





IOL Chemicals And Pharmaceuticals Limited

This presentation has been prepared by IOL Chemicals & Pharmaceuticals Limited (the "Companies", IOL) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the companies will be made except by means of a statutory offering document containing detailed information about the Companies.

This Presentation has been prepared by the Companies based on information and data which the Companies considers reliable, but the Companies makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the companies market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the companies ability to successfully implement its strategy, the companies future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the companies market preferences and its exposure to market risks, as well as other risks. The companies actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The companies assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the companies and the companies is not responsible for such third party statements and projections.

Table of Contents

IOL Chemicals And Pharmaceuticals Limited

01 IOLCP at a glance

- About IOL Chemicals and Pharmaceuticals Ltd.
- Q1FY24 Performance
- Geographical & Segmental Highlights

02 Financial Highlights

- Quarterly Income Statement
- Growing top-line
- Building Assets
- Cash Flow Statement
- 5 years performance highlights
- Diversified Revenue base

03 Company Overview

- The Journey
- Core management team
- Board of Directors
- Certification & Accreditation

04 Business Overview

- Pharmaceutical-Building API Portfolio
- Specialty Chemicals-Capitalizing on global demand
- Manufacturing Facilities
- Ensuring a Sustainable Tomorrow Through ESG Initiatives

05 Industry Overview

- Pharmaceutical-Emerging strongly out of pandemic
- Chemical Sector- An era of sustained robust growth

06 Way Forward

- Charting a path to success
- Expanding the non-Ibuprofen business
- Summary





Incorporated in 1986, IOLCP is one of the leading API Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities






5


Operational Highlights


- CARE Rating has reaffirmed to A+ with a stable outlook
- Commenced plant for Acetic Anhydride, which shall be used for captive consumption as well as merchant sale
- Progressing a product registration from NMPA, China





Geographical and Segmental highlights

- IOL Chemicals And Pharmaceuticals Limited









FINANCIAL HIGHLIGHTS



Particulars (Rs. Cr)	Q1 FY24	Q1 FY23	YoY	Q4 FY23
Revenues	563.2	565.0		587.2
Other Income	7.1	5.2		8.7
Total Income	570.3	570.2		595.9
Total Expenses	490.4	509.0		491.4
EBITDA	79.9	61.2	30.6%	104.5
EBITDA Margin (%)	14.0%	10.7%	330 bps	17.5%
Depreciation	14.4	11.0		12.1
Finance Cost	4.0	3.4		4.9
Profit Before Exceptional Items	61.5	46.8		87.5
Exceptional items (Expense) / Income				
Profit Before Tax	61.5	46.8	31.4%	87.5
Tax	15.3	11.9		22.2
Profit After Tax	46.2	34.9	32.4%	65.3
PAT Margin (%)	8.1%	6.2%	190bps	11.0%
Other Comprehensive Income	-1.2	-0.5		0.8
Total Comprehensive Income	45.0	34.4		66.1
Basic & Diluted EPS (INR)	7.9	5.9		11.1



Yearly Income Statement



Particulars (Rs. Cr)	FY23	FY22	YoY
Revenues	2,217.1	2,184.0	
Other Income	25.6	32.0	
Total Income	2,242.7	2,216.0	1.2%
Total Expenses	1,990.6	1,927.6	
EBITDA	252.1	288.4	-12.6%
EBITDA Margin (%)	11.2%	13.0%	-180 bps
Depreciation	46.1	43.3	
Finance Cost	16.5	8.3	
Profit Before Exceptional Items	189.5	236.8	
Exceptional items (Expense) / Income	-	-13.9	
Profit Before Tax	189.5	222.9	
Tax	49.5	57.2	
Profit After Tax	140.0	165.7	-15.5%
PAT Margin (%)	6.2%	7.5%	-130 bps
Other Comprehensive Income	-0.2	-0.6	
Total Comprehensive Income	139.8	165.1	
Basic & Diluted EPS (INR)	23.8	28.2	

Growing top-line



Particulars (Rs. Cr)	FY18	FY19	FY20	FY21	FY22	FY23
Revenues	983.3	1,685.3	1,894.5	1,967.0	2,184.0	2,217.1
Other Income	6.3	10.4	16.0	24.3	32.0	25.6
Total Income	989.6	1,695.7	1,910.5	1,991.3	2,216.0	2,242.7
Total Expenses	863.7	1,275.7	1,320.6	1,375.2	1,927.6	1,990.6
EBITDA	125.9	420.0	589.9	616.1	288.4	252.1
EBITDA Margin (%)	12.7%	24.8%	30.9%	30.9%	13.0%	11.2%
Depreciation	30.2	32.5	35.7	38.9	43.3	46.1
Finance Cost	64.4	51.4	20.9	5.8	8.3	16.5
Profit Before Exceptional Items	31.3	336.1	533.3	571.4	236.8	189.5
Exceptional items (Expense) / Income					-13.9	
Profit Before Tax	31.3	336.1	533.3	571.4	222.9	189.5
Tax	3.6	99.5	172	126.8	57.2	49.5
Profit After Tax	27.7	236.6	361.3	444.6	165.7	140.0
PAT Margin (%)	2.8%	14.0%	18.9%	22.3%	7.5%	6.2%
Other Comprehensive Income	-0.6	-1.4	-1.52	-2.14	-0.6	-0.2
Total Comprehensive Income	27.1	235.2	359.8	442.5	165.1	139.8
Diluted EPS (INR)	4.93	42.1	63.4	76.2	28.2	23.8

Building assets



Balance Sheet (Rs. Cr)	FY18	FY19	FY20	FY21	FY22	FY23
Shareholders' Funds	215.7	474.3	813.5	1260.4	1390.3	1506.6
Debt	421.9	284.0	56.0	0.0	0.0	0.0
Total Non-current Liabilities	33.6	20.8	79.7	59.1	56.6	58.1
Total Current Liabilities	180.9	162.8	220.6	290.6	513.4	455.9
Equity & Liabilities	852.1	941.9	1169.8	1610.1	1960.3	2020.6
Fixed Assets	412.6	438.7	488.2	560.6	665.8	841.0
Fixed Deposits (Non-Current)	1.9	6.9	5.3	21.2	203.7	230.7
Other Non-Current Assets	12.9	8.3	5.4	6.0	12.0	29.8
Non Current Assets	427.4	453.8	498.9	587.8	881.5	1101.5
Investments	0.1	0.1	0.1	1.2	2.4	2.6
Cash & Bank Balances	17.3	29.6	154.7	364.8	137.9	20.9
Other Current Assets	407.3	458.4	516.1	656.3	938.5	895.6
Current Assets	424.7	488.1	670.9	1022.3	1078.8	919.1
Assets	852.1	941.9	1169.8	1610.1	1960.3	2020.6

11



Particulars (Rs. Cr)	FY19	FY20	FY21	FY22	FY23
Profit before tax	336.15	533.24	571.39	222.84	189.49
Adjustments for: Non Cash Items / Other Investment or Financial Items	82.35	51.93	27.15	33.12	44.42
Operating profit before working capital changes	418.50	585.17	598.54	255.96	233.91
Changes in working capital	-77.64	2.78	-76.51	-102.34	-63.67
Cash generated from Operations	340.86	587.95	522.03	153.62	170.24
Income tax paid(net)	-67.69	-117.15	-142.25	-62.58	-47.10
Net cash flow from operating activities	273.17	470.80	379.78	91.04	123.14
Net cash flow from investing activities	-63.04	-184.23	-317.25	-120.62	-119.19
Net cash from financing activities	-197.46	-271.89	-58.28	-1.64	-4.11
Net Increase/Decrease in Cash and Cash equivalents	12.67	14.68	4.25	-31.22	-0.16
Cash & Cash equivalents at the beginning of the period	0.74	13.41	28.09	32.34	1.12
Cash & Cash equivalents at the end of the period	13.41	28.09	32.34	1.12	0.96



5-years Performance


IOL Chemicals And Pharmaceuticals Limited



Diversified revenue base



14




* Amt in Rs.crore

COMPANY OVERVIEW

The Journey

IOL Chemicals And Pharmaceuticals Limited



Core management team

Varinder Gupta (Managing Director)

 Wide and rich experience of more than 35 years in the chemical & fertilizer industry and along with a comprehensive approach and strong Pharma API industry oversight has paved a way for innovation and excellence



Abhiraj Gupta (Executive Director*)

• Possesses requisite qualification and experience in the Company's business. He oversees the nonibuprofen API and chemical business, R&D, regulatory, digital marketing, and strategic decisions. The non-ibuprofen API business is doing good and meeting its targets under his leadership.

Vikas Vij (Chief Executive Officer*)

- Dynamic career spanning over 30 years showing year-on-year success in achieving profitability and business growth for various companies like Sun Pharma, Ranbaxy, Cipla leading API segment and Access Business Unit among others
- Has handled leadership roles across Pharma Value chain and Speciality Chemicals and achieved multi-million dollar sales target



 Academically equipped with knowledge and possesses organizational capacity. He has worked in strategic department of the Company and played a main role in guiding Chemical and Pharmaceutical business of the company. He has been vital to the functioning of the company over the last 7 years

Kushal Kumar Rana (Director - Works)

- Bachelor's in Chemistry, Physics, Math and Master's degree in Chemistry
- Over 30 years in the pharmaceutical industry in companies like Morepen Laboratories, Chemiplast Industries
- His expertise lies in looking after quality assurance, quality control & corporate regulatory affairs



Board of Directors



Rajender Mohan Malla

(Chairman and Independent Director)

- With four decades of experience held top and significant decision-making positions in Banks, Financial Institutions & NBFCs
- In his most recent executive roles, he was MD & CEO of PTC India Financial Services Limited (PFS), and prior to that CMD of IDBI

Dr. Sandhya Mehta

(Independent Director)

- Dr. Sandhya is working as the principal of Guru Nanak Institute of Management & technology, Ludhiana and has vast 22 year experience to her credit
- She has published seven books in addition to numerous papers published in reputed National & international Journals



- Over 35 year's experience of banking and financial services
- Most recently he was General Manager of Punjab National Bank and headed entire operations of bank in State of Punjab from 2010 to 2015

Sharad Tyagi (Independent Director)

- Over 35 years of intrapreneurship in India and international markets in diverse industries including pharmaceuticals, OTC, automotive catalysts and specialty chemicals
- Most recently until December 2020, he was the Managing Director for Boehringer Ingelheim (BI) (2009-2020), India

Certifications and Accreditations

- IOL Chemicals And Pharmaceuticals Limited



BUSINESS OVERVIEW

IOL Chemicals And Pharmaceuticals Limited


IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen having a capacity of 12000+ MT

- Dedicated USFDA approved facilities for Ibuprofen
- Among the largest producer of Metformin in India
- EUGMP Certification from National Institute of Pharmacy and Nutrition, Hungary for 12 APIs.
- Received approval from Korean FDA for 2 products and 6 products from Russian regulatory Authorities
- Filed 12 DMFs with USFDA & 5 CEP with EDQM.

Product Portfolio

Existing Porffolio					
Ibuprofen	Clopidogrel	Losartan Potassium			
Ibuprofen Lysinate	Pantoprazole Sodium	Levetiracetam			
Ibuprofen Sodium	Fenofibrate	Paracetamol			
Dex-Ibuprofen	Gabapentin				
Metformin HCL	Lamotrigine				


Product application across various therapeutic areas



IOL Chemicals And Pharmaceuticals Limited

IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 TPA Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 1,00,000 TPA

- India's second largest manufacturer for Iso Butyl Benzene (IBB) with ~30% global share
- Received REACH Certificate for ethyl acetate and is exported to over 40 countries worldwide
- IBB, MCA and Acetyl Chloride are key starting materials for Ibuprofen
- Captive consumption of Mono Chloro Acetic Acid with 7,200 TPA capacity and Acetyl Chloride with 5200 TPA capacity
- Commenced plant for Acetic Anhydride with 25,000 TPA, which shall be used for captive consumption as well as merchant sale



Product application across diversified industries Food processing Textiles Flexible Packaging Ink **Paints** Pharma Chemical Intermediate Pesticides (\triangle) 22

Manufacturing facilities











API manufactured in batch manner and intermediates & Specialty chemicals in continuous product delivery manner based on DCS technology


Manufacturing facilities involves -Reactions, Filteration, Centrifugation, Drying, Blending & Sieving, Micronization operation Dedicated and multiproduct blocks involved in manufacturing of APIs

Four stage treatment zero discharge ETP, solvent recovery plants & EHS cell as a part of the facility Facility is coupled with ISO class-8 HVAC system, PSA Nitrogen & Purified water along with 127 MTPH steam generation capacity with multiple boilers

Dedicated decentralized utilities from -20 to 275 deg.C temp and dedicated co-generation plant of 17MW

Research & Development





Working on generic molecules with latest equipment & techniques for process development





In-house development of multi step products

23



Environment


- Committed to ensure that our operations have minimal impact on the environment
- Constantly monitoring environmental footprints and implementing relevant initiatives.
- We have installed a Continuous Air Quality Monitoring System (CAAQMS) to monitor real-time concentrations of all key pollutants in ambient air.
 - Governance

We prioritize strong and effective corporate governance to ensure the best interests of all our stakeholders.

Social

- Committed towards making a difference in the lives of communities surrounding our operations through our CSR efforts
- We strive to create sustainable and meaningful change through our philanthropic efforts, reflecting our core values and commitment to social responsibility.

- Our continuous efforts have resulted in a 4.58% reduction in Scope-01 greenhouse gas (GHG) emissions during FY 2022-23.
- Our targets include a reduction in Scope-01 emissions by 45.21% and 100% reduction in Scope-02 emissions by 2035, based on the baseline emissions of FY 2021-22



INDUSTRY OVERVIEW

Pharmaceuticals - Emerging strongly out of pandemic




Indian API Market

٠

•


World Pharmaceutical Industry






to \$8 billion, compared with a little over \$9 billion in FY22 The shadien shows inductors is making conicas

 The Indian pharma industry is making serious efforts towards a shift from volume-based products to value-based products




Specialty Chemicals - an era of sustained robust growth



- The sector is projected to grow at 11-12% during 2021-27 and 7-10% during 2027-40 tripling its global market share by 2040.
- Specialty chemicals is expected to be a net exporter. By 2040, its net exports are expected to rise by around ten times, from about USD 2 billion in 2021 to USD 21 billion
- India has cost advantage in production of Iso-Butyl Benzene (IBB) compared to China (15% lower) and Germany (35% lower) commanding two-third of the global market

Factors driving growth of specialty chemicals in India



Indian Specialty Chemical Industry

Year	Chemical	Specialty Chemicals	Growth
2021	US\$170-180 Billion	US\$32 Billion	9-10%
2040	US\$ 850-1000 Billion	US\$140-190 Billion	11.5% (2021-27) 7-9.5% (2027-40)

Source: McKinsey - India: The Next Chemicals Manufacturing Hub, March 2023




27




WAY FORWARD

Charting a path to success

IOL Chemicals And Pharmaceuticals Limited



Expanding the non-Ibuprofen business







Pharmaceutical Segment

- Moving towards a well diversified product portfolio, that is a shift towards the non-ibuprofen business.
- We have successfully implemented manufacturing processes for Pantoprazole, Clopidogrel, Levetiracetam, and other APIs.
- Our creation of synergistic segments, such as combination products like Vildagliptin and Sitagliptin with Metformin and Losartan and Valsartan, further diversifies our portfolio and positions us for growth in specific therapeutic areas.

Specialty Chemical Segment

- Commenced plant for Acetic Anhydride with 25,000 TPA , which shall be used for captive consumption as well as merchant sale
- Explored opportunities in diverse product categories such as plasticizers, amines, and diketene derivatives, enabling us to identify new products for future growth.



Thank You

Company :

Investor Relations Advisors :

IOL Chemicals & Pharmaceuticals Ltd.

Mr. Pardeep Kumar Khanna, CFO pardeepkhanna@iolcp.com

www.iolcp.com

Adfactorspr Pvt. Ltd.

Darshan Mankad darshan.mankad@adfactorspr.com

Hanishi Shah hanishi.shah@adfactorspr.com

www.adfactorspr.com